VADDI KRISHNA (President, CEO) purchased 51.0% of their position (675K shares) of PRELUDE THERAPEUTICS INC on the open market
Open‑market purchase worth $467.4K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 3/27/2025ACC: 0001562180-25-002778
DirectorOfficer· President, CEO
Since Sep 2020
+675K
Net shares
Net buyer
$467.4K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
675K acquired
Non-Derivative Transactions1
Common Stock
Direct
Shares
+675K
Price / share
$0.69
Trade value
$467.44K
% of position
51.0%
3/25/2025
1.32M→2M
Total
Net shares
+675K
Net value
$467.44K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/25/2025 | P · Purchase | +675K | $0.69 | $467.44K | 51.0% | 1.32M | 2M |
| Total | +675K | $467.44K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)4
Common Stock
IndirectShares owned423.65K
Common Stock
IndirectShares owned142.55K
Common Stock
IndirectShares owned551.77K
Common Stock
IndirectShares owned551.78K
Total
1.67M indirect1.67M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 423.65K | Indirect |
| Common Stock | 142.55K | Indirect |
| Common Stock | 551.77K | Indirect |
| Common Stock | 551.78K | Indirect |
| Total | 1.67M | 1.67M indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported